REG - LungLife AI, INC - Clinical validation study update

LungLife AIAnnouncement

28/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230928:nRSb9096Na&default-theme=true

RNS Number : 9096N  LungLife AI, INC  28 September 2023

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Clinical validation study update

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the
early detection of lung cancer, provides an update on the Company's clinical
validation study for its LungLB® test.

 

As stated in the Company's half-year report
(https://lunglifeai.com/wp-content/uploads/2023/08/LLAI-Interim-Results-2023-08.08.23.pdf)
on 8 August 2023, LungLife is currently focussed on preparing data from the
clinical validation study for detailed analysis, which was expected to be
concluded by the end of September 2023. Due to delays in the provision of data
from study sites, full database lock, and the consequent knock-on impact on
ability to analyse the data we now expect this to be concluded in Q4 2023.

 

For further information please contact:

 

 LungLife AI, Inc.                                         www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                          Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Joint Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Goodbody (Joint Broker)                                   Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420

 Tom Nicholson / Stephen Kane

 Walbrook PR Limited                                        Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                           (mailto:LungLifeAI@walbrookpr.com)
 Paul McManus / Alice Woodings / Phillip Marriage          Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESLRMLTMTMTBFJ